Drug Development

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

With strong Phase 1 data and key FDA backing, Trethera's TRE-515 is advancing as a 'pipeline-in-a-product' for a wide range of diseases.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

Following key FDA progress for its oral osteoporosis drug, Entera Bio's CEO and board members are buying up company stock, signaling deep confidence.

New 3D human tissue models show groundbreaking promise in predicting toxicity for advanced cancer therapies, heralding a major shift away from animal testing.

Backed by a proven billion-dollar impact model, 14 new startups are using AI, neuroscience, and philanthropy to revolutionize mental healthcare.

From its unique seat at the World Government Summit, CanSinoBIO unveils its next-gen vaccine pipeline and global strategy to fight humanity's oldest diseases.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

With rapid trial enrollment for a novel drug, Pulmovant offers a potential lifeline for patients with PH-ILD, a condition with few to no options.

Viking Therapeutics' upcoming earnings call is about more than just financials. Investors are focused on key pipeline updates for its obesity and MASH drugs.

After a blockbuster IPO raised nearly $300 million, dermatologist-founded Veradermics is poised to challenge the hair loss market with its new oral pill.

iVeena promotes key execs as it prepares for clinical trials of a novel eye drop that could reshape pediatric myopia treatment worldwide.

A simple nasal spray could offer immediate, broad protection against the flu. New landmark studies show how this antibody-based shield could revolutionize prevention.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

Current blood thinners carry a risky trade-off. A new class of drugs targeting Factor XIa could prevent deadly clots without the dangerous bleeding.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.